Amy Sheridan-Hill, co-founder of the H-ABC Foundation, and Dan Williams in major Mirror story about hopes for new drug
SynaptixBio’s collaboration with leading global drug researcher Evotec featured in European Biotechnology Magazine
Dan Williams and Amy Sheridan-Hill, whose son Frankie suffers from H-ABC, interviewed for the Evening Standard.
In a major article, Dan Williams considers how to overcome obstacles in rare disease treatment
Leading biotech appoints senior industry figure as Chief Medical Officer to define clinical strategy and oversee trials
Bioscience Today features major Dan Williams article about collaboration driving rare disease drug development
Dan Williams says Big Pharma could help accelerate market introduction for rare disease drugs
SynaptixBio awarded second FDA Orphan Drug Designation to boost search for rare disease therapies
BBC features TUBB4A leukodystrophy case study – Dan Williams contribution highlights lack of widespread awareness of rare diseases
Dan Williams interviewed for prestigious journal - Major International Clinical Trials feature showcases SynaptixBio story
Leading biotech firm welcomes new NHS rapid diagnostic service for rare diseases, but says wider newborn screening is key
SynaptixBio awarded prestigious Innovate UK grant to expand search for rare disease therapies
Oxford biotech firm secures £13.2m to develop first treatment for rare, incurable, deadly disease.
British biotech firm secures FDA rare paediatric disease designation